June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Circulating miRNAs as Biomarkers of Retinal Toxicity
Author Affiliations & Notes
  • Qinghai Peng
    Pfizer, San Diego, CA
  • Wenhu Huang
    Pfizer, San Diego, CA
  • Walter Collette
    Pfizer, San Diego, CA
  • Michelle Twamley
    Pfizer, San Diego, CA
  • Shirley Aguirre
    Pfizer, San Diego, CA
  • Annette John-Baptiste
    Pfizer, San Diego, CA
  • Footnotes
    Commercial Relationships Qinghai Peng, None; Wenhu Huang, None; Walter Collette, None; Michelle Twamley, Pfizer, Inc. (E); Shirley Aguirre, None; Annette John-Baptiste, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1947. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Qinghai Peng, Wenhu Huang, Walter Collette, Michelle Twamley, Shirley Aguirre, Annette John-Baptiste; Circulating miRNAs as Biomarkers of Retinal Toxicity. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1947.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To examine whether circulating retinal-enriched microRNAs were altered post treatment in a drug induced retinal toxicity study in rat.

Methods: Wistar Hans rats were administered a single intravitreal injection of either a pan-CDK inhibitor (10 or 30 µg/eye) or a HSP90 inhibitor (9 or 27 µg/eye). EDTA whole blood samples were collected predose, and on days 1, 3 and 7 post dose. Retinal-enriched miRNAs and the liver-enriched miR-192 (used as a control) were analyzed by qRT-PCR. Electroretinography (ERG) was performed predose and at end of study to assess retinal function. Eyes were collected either on day 8 or at 2 weeks post dose and processed for histopathologic evaluation.

Results: Elevations of plasma miR-124a, miR-96, and miR-183 peaked on day 3 post dose in the pan-CDKi high dosed animals demonstrating greater than 300X, 10X and 6X fold increases respectively in a time-dependent manner . The low dose group of the pan-CDKi treated animals demonstrated slight elevations of miR-124a, miR-96 and miR-183. Neither dose group in the pan-CDKi treated animals demonstrated any change in miR-192 and retinal degeneration was confirmed by ERG and histopathology. Comparatively, the HSP90 treated group, exhibited no changes in miRNA levels, ERG or histopathology.

Conclusions: This study demonstrated plasma miR-96, miR-124a, and miR-183 are strong contenders as retinal toxicity biomarkers. Although these miRNAs need additional validation whether they truly predict retinal toxicity or not prior to histopathology, these results provide promise for further test using additional retinal toxicants.

Keywords: 695 retinal degenerations: cell biology • 620 ocular irritancy/toxicity testing  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.